Controversies in Acute Myeloid Leukemia: Is Monitoring Minimal Residual Disease Clinically Relevant?

This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize current methods used to monitor minimal residual disease in acute myeloid leukemia.
  • Describe the clinical utility and caveats of the methods used to monitor minimal residual disease in AML.
Additional information

This activity is supported by educational funding provided by Amgen.

This activity is supported by independent educational grants from:

  • AbbVie
  • Incyte

This activity is supported by educational grants from:

  • Abbott’s molecular business
  • Agios Pharmaceuticals
  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Gilead Sciences, Medical Affairs
  • Jazz Pharmaceuticals, Inc.
  • MEI Pharma
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • Pfizer
  • Seattle Genetics, Inc.
  • Takeda Oncology
  • Verastem
Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
Course expires: 

Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Richard M. Stone, MD
Dana-Farber Cancer Institute


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses the following relevant financial relationships:
Jessica K. Altman, MD
Astellas Pharma US, Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor

Richard M. Stone, MD
AbbVie Inc.: Consulting Fees, Honoraria
Actinium Pharmaceuticals, Inc.: Officer, Director or any other fiduciary role; Scientific Advisor
Agios Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Amgen Inc.: Consulting Fees, Honoraria
Argenx: Consulting Fees, Honoraria
Arog Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Astellas Pharma US, Inc.: Consulting Fees, Honoraria
Celator Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Consulting Fees, Honoraria
FUJIFILM Pharmaceuticals U.S.A., Inc.: Consulting Fees, Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria
Jazz Pharmaceuticals: Consulting Fees, Honoraria
Juno Therapeutics, Inc.: Consulting Fees, Honoraria
Karyopharm Therapeutics Inc.: Consulting Fees, Honoraria
Merck & Co., Inc.: Consulting Fees, Honoraria
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support
Orsenix Holdings BV: Consulting Fees, Honoraria
Otsuka America Pharmaceutical, Inc.: Consulting Fees, Honoraria
Pfizer Inc.: Consulting Fees, Honoraria
Rafael Pharmaceuticals, Inc. (formerly Cornerstone Pharmaceuticals, Inc.): Consulting Fees, Honoraria
Roche Laboratories, Inc.: Consulting Fees, Honoraria
Seattle Genetics, Inc.: Consulting Fees, Honoraria
Sumitomo Dainippon Pharma Co., Ltd.: Consulting Fees, Honoraria

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Donald Harting, MA, ELS, CHCP; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Ndiya Ogba, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.

National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.75 contact hours.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: 0836-0000-17-105-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: